<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38174103</PMID><DateRevised><Year>2024</Year><Month>01</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2052-2975</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>New microbes and new infections</Title><ISOAbbreviation>New Microbes New Infect</ISOAbbreviation></Journal><ArticleTitle>Long COVID-associated symptoms prevalent in both SARS-CoV-2 positive and negative individuals: A prospective follow-up study.</ArticleTitle><Pagination><StartPage>101209</StartPage><MedlinePgn>101209</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101209</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nmni.2023.101209</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Research into persistent symptoms among SARS-CoV-2-positive i.e. CoV(+) patients mostly focuses on hospitalized individuals. Our prospective follow-up study compares long COVID-associated symptoms among laboratory-confirmed CoV(+) and SARS-CoV-2 negative [CoV(-)] individuals.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">SARS-CoV-2 RT-PCR-tested volunteers were recruited into four cohorts: 1) CoV(+) outpatients, 2) CoV(-) outpatients, 3) CoV(+) intensive care unit (ICU) inpatients, and 4) CoV(+) non-ICU inpatients. Neutralizing antibodies were assessed and questionnaires filled in at enrolment and days 90-120, 121-180, 181-270, 271-365, and 365-533.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 1326 participants, 1191 were CoV(+): 46 ICU, 123 non-ICU, and 1022 outpatients; 135 were CoV(-) outpatient controls. Both CoV(+) outpatients and CoV(-) controls showed high overall symptom rates at all time points. More prevalent among CoV(+) than CoV(-) outpatients were only impaired olfaction and taste; many others proved more frequent for CoV(-) participants. At &#x2265;181 days, fatigue, dyspnoea, various neuropsychological symptoms and several others were recorded more often for CoV(+) inpatients than outpatients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Long COVID-associated symptoms were more frequent among hospitalized than non-hospitalized CoV(+) participants. As for outpatients, only impaired olfaction and taste showed higher rates in the CoV(+) group; some symptoms proved even more common among those CoV(-). Besides suggesting low long COVID prevalences for outpatients, our results highlight the weight of negative controls.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kantele</LastName><ForeName>Anu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Meilahti Infectious Diseases and Vaccine Research Center, MeiVac, Biomedicum 1, Haartmaninkatu 8, Helsinki University Hospital and University of Helsinki, 00290, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Microbiome Research Program, Faculty of Medicine, Haartmaninkatu 4, 00014, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paajanen</LastName><ForeName>Juuso</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietil&#xe4;</LastName><ForeName>Jukka-Pekka</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Meilahti Infectious Diseases and Vaccine Research Center, MeiVac, Biomedicum 1, Haartmaninkatu 8, Helsinki University Hospital and University of Helsinki, 00290, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Microbiome Research Program, Faculty of Medicine, Haartmaninkatu 4, 00014, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vapalahti</LastName><ForeName>Olli</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Viral Zoonoses Research Unit, Departments of Virology and Veterinary Biosciences, Faculties of Medicine and Veterinary Medicine, 00014, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helsinki University Hospital Diagnostic Center, HUSLAB, Clinical Microbiology, Topeliuksenkatu 32, 00290, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pakkanen</LastName><ForeName>Sari H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Meilahti Infectious Diseases and Vaccine Research Center, MeiVac, Biomedicum 1, Haartmaninkatu 8, Helsinki University Hospital and University of Helsinki, 00290, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Microbiome Research Program, Faculty of Medicine, Haartmaninkatu 4, 00014, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe4;&#xe4;veri</LastName><ForeName>Tinja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Meilahti Infectious Diseases and Vaccine Research Center, MeiVac, Biomedicum 1, Haartmaninkatu 8, Helsinki University Hospital and University of Helsinki, 00290, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Microbiome Research Program, Faculty of Medicine, Haartmaninkatu 4, 00014, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helsinki University Hospital Diagnostic Center, HUSLAB, Clinical Microbiology, Topeliuksenkatu 32, 00290, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, Aalto University, PO Box 15400, FI-00076, AALTO, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>New Microbes New Infect</MedlineTA><NlmUniqueID>101624750</NlmUniqueID><ISSNLinking>2052-2975</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Follow-up study</Keyword><Keyword MajorTopicYN="N">Long covid</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Tinja L&#xe4;&#xe4;veri: Honoraria (Pfizer) unrelated to this article. Anu Kantele: Research grants (Valneva, Pfizer) unrelated to this article. None of the authors declare any competing interests that could have influenced the work reported in this paper. Other authors declare no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>11</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38174103</ArticleId><ArticleId IdType="pmc">PMC10761764</ArticleId><ArticleId IdType="doi">10.1016/j.nmni.2023.101209</ArticleId><ArticleId IdType="pii">S2052-2975(23)00128-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan V.M., McGroder C., Stevens J.S., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;605. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly J.D., Curteis T., Rawal A., Murton M., Clark L.J., Jafry Z., et al. SARS-CoV-2 post-acute sequelae in previously hospitalised patients: systematic literature review and meta-analysis. Eur Respir Rev. 2023;32 doi: 10.1183/16000617.0254-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0254-2022</ArticleId><ArticleId IdType="pmc">PMC10336551</ArticleId><ArticleId IdType="pubmed">37437914</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., Sun B.A., Ssentongo A.E., Ba D.M., Parsons N., Pudel G.R., et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4:1&#x2013;17. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A., Shetty A., Delanerolle G., Zeng Y., Zhang Y., Raymont V., et al. A&#xa0;systematic review and meta-analysis of long COVID symptoms. Syst Rev. 2023;12:88. doi: 10.1186/s13643-023-02250-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-023-02250-0</ArticleId><ArticleId IdType="pmc">PMC10220332</ArticleId><ArticleId IdType="pubmed">37245047</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S., Rosell A., Phillipson M., Mangsbo M.S., Nilsson P., Hober S., et al. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. 2021;325:2015&#x2013;2016. doi: 10.1001/jama.2021.5612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.5612</ArticleId><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund L.C., Hallas J., Nielsen H., Koch A., Mogensen S.H., Brun N.C., et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. 2021;21:1373&#x2013;1382. doi: 10.1016/S1473-3099(21)00211-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00211-5</ArticleId><ArticleId IdType="pmc">PMC8110209</ArticleId><ArticleId IdType="pubmed">33984263</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;raas A., Kalleberg K.T., Dahl J.A., Soraas C.L., Myklebust T.A., Axelsen E., et al. Persisting symptoms three to eight months after non-hospitalized COVID-19, a prospective cohort study. PLoS One. 2021;16:1&#x2013;13. doi: 10.1371/journal.pone.0256142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0256142</ArticleId><ArticleId IdType="pmc">PMC8389372</ArticleId><ArticleId IdType="pubmed">34437579</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Bowe B., Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun. 2021;12:1&#x2013;12. doi: 10.1038/s41467-021-26513-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26513-3</ArticleId><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A.V., van Zon S.K.R., olde Hartman T.C., Rosmalen J.G.M. Persistence of somatic symptoms after COVID-19 in The Netherlands: an observational cohort study. Lancet. 2022;400:452&#x2013;461. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M., Braillard O., Chappuis F., Courvoisier D.S., Kaiser L., Soccal P.M., et al. One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals. J&#xa0;Intern Med. 2022;292:103&#x2013;115. doi: 10.1111/joim.13482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13482</ArticleId><ArticleId IdType="pmc">PMC9115262</ArticleId><ArticleId IdType="pubmed">35555926</ArticleId></ArticleIdList></Reference><Reference><Citation>Robineau O., Zins M., Touvier M., Wiernik E., Lemogne C., de Lamballerie X., et al. Long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution. JAMA Netw Open. 2022;5 doi: 10.1001/jamanetworkopen.2022.40985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.40985</ArticleId><ArticleId IdType="pmc">PMC9647489</ArticleId><ArticleId IdType="pubmed">36350653</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rensen A.I.V., Spiliopoulos L., Bager P., Nielsen N.M., Hansen J.V., Koch A., et al. A&#xa0;nationwide questionnaire study of post-acute symptoms and health problems after SARS-CoV-2 infection in Denmark. Nat Commun. 2022;13:4213. doi: 10.1038/s41467-022-31897-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31897-x</ArticleId><ArticleId IdType="pmc">PMC9302226</ArticleId><ArticleId IdType="pubmed">35864108</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V.T., Porcher R., Pane I., Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun. 2022;13:1812. doi: 10.1038/s41467-022-29513-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29513-z</ArticleId><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>Strahm C., Seneghini M., G&#xfc;sewell S., Egger T., Leal-Neto O., Brucher A., et al. Symptoms compatible with long coronavirus disease (COVID) in healthcare workers with and without Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection&#x2014;results of a prospective multicenter cohort. Clin Infect Dis. 2022;2:1&#x2013;9. doi: 10.1093/cid/ciac054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac054</ArticleId><ArticleId IdType="pmc">PMC9383387</ArticleId><ArticleId IdType="pubmed">35090015</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisk L.E., Gottlieb M.A., Spatz E.S., Yu H., Wang R.C., Slovis B.H., et al. Association of initial SARS-CoV-2 test positivity with patient-reported well-being 3 months after a symptomatic illness. JAMA Netw Open. 2022;5 doi: 10.1001/jamanetworkopen.2022.44486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.44486</ArticleId><ArticleId IdType="pmc">PMC9716377</ArticleId><ArticleId IdType="pubmed">36454572</ArticleId></ArticleIdList></Reference><Reference><Citation>Spatz E.S., Gottlieb M., Wisk L.E., Anderson J., Chang A.M., Gentile N.L., et al. Three-month symptom profiles among symptomatic adults with positive and negative Severe Acute Respiratory Syndrome Coronavirus 2 tests: a prospective cohort study from the INSPIRE Group. Clin Infect Dis. 2023;76:1559&#x2013;1566. doi: 10.1093/cid/ciac966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac966</ArticleId><ArticleId IdType="pmc">PMC11361781</ArticleId><ArticleId IdType="pubmed">36573005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb M., Spatz E.S., Yu H., Wisk L.E., Elmore J.G., Gentile N.L., et al. Long COVID clinical phenotypes up to 6 months after infection identified by latent class analysis of self-reported symptoms. Open Forum Infect Dis. 2023;10:ofad277. doi: 10.1093/ofid/ofad277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad277</ArticleId><ArticleId IdType="pmc">PMC10327879</ArticleId><ArticleId IdType="pubmed">37426952</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb M., Wang R.C., Yu H., Spatz E.S., Montoy J.C.C., Rodriguez R.M., et al. Severe fatigue and persistent symptoms at 3 months following Severe Acute Respiratory Syndrome Coronavirus 2 infections during the pre-Delta, Delta, and Omicron time periods: a multicenter prospective cohort study. Clin Infect Dis. 2023;76:1930&#x2013;1941. doi: 10.1093/cid/ciad045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad045</ArticleId><ArticleId IdType="pmc">PMC10249989</ArticleId><ArticleId IdType="pubmed">36705268</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., Sudre C.H., Molteni E., Berry S., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43&#x2013;55. doi: 10.1016/S1473-3099(21)00460-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Haveri A., Smura T., Kuivanen S., &#xd6;sterlund P., Hepojoki J., Ikonen N., et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 2020;25 doi: 10.2807/1560-7917.ES.2020.25.11.2000266.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.11.2000266</ArticleId><ArticleId IdType="pmc">PMC7096774</ArticleId><ArticleId IdType="pubmed">32209163</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaira L.A., Salzano G., Le Bon S.D., Maglio A., Petrocelli M., Steffens Y., et al. Prevalence of persistent olfactory disorders in patients with COVID-19: a psychophysical case-control study with 1-year follow-up. Otolaryngol Head Neck Surg. 2022;167:183&#x2013;186. doi: 10.1177/01945998211061511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01945998211061511</ArticleId><ArticleId IdType="pubmed">34813382</ArticleId></ArticleIdList></Reference><Reference><Citation>Croy I., Nordin S., Hummel T. Olfactory disorders and quality of life--an updated review. Chem Senses. 2014;39:185&#x2013;194. doi: 10.1093/chemse/bjt072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/chemse/bjt072</ArticleId><ArticleId IdType="pubmed">24429163</ArticleId></ArticleIdList></Reference><Reference><Citation>Santomauro D.F., Mantilla Herrera A.M., Shadid J., Zheng P., Ashbaugh C., et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:1700&#x2013;1712. doi: 10.1016/S0140-6736(21)02143-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02143-7</ArticleId><ArticleId IdType="pmc">PMC8500697</ArticleId><ArticleId IdType="pubmed">34634250</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolino D., Cesari M. Fatigue in the COVID-19 pandemic. Lancet Heal Longev. 2022;3:e128&#x2013;e129. doi: 10.1016/S2666-7568(22)00029-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(22)00029-0</ArticleId><ArticleId IdType="pmc">PMC8901180</ArticleId><ArticleId IdType="pubmed">35282597</ArticleId></ArticleIdList></Reference><Reference><Citation>Antipova A. Analysis of the COVID-19 impacts on employment and unemployment across the multi-dimensional social disadvantaged areas. Soc Sci Humanit open. 2021;4 doi: 10.1016/j.ssaho.2021.100224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ssaho.2021.100224</ArticleId><ArticleId IdType="pmc">PMC8557984</ArticleId><ArticleId IdType="pubmed">34746750</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVergne S.M., Stromberg S., Baxter B.A., Webb T.L., Dutt T.S., Berry K., et al. A&#xa0;longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae. BMC Infect Dis. 2021;21:1&#x2013;9. doi: 10.1186/s12879-021-06359-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06359-2</ArticleId><ArticleId IdType="pmc">PMC8276222</ArticleId><ArticleId IdType="pubmed">34256735</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuel J.W., Lauria E., Lovey T., Zweifel S., Meier M.I., Z&#xfc;st R., et al. Persistence, prevalence, and polymorphism of sequelae after COVID-19 in unvaccinated, young adults of the Swiss Armed Forces: a longitudinal, cohort study (LoCoMo) Lancet Infect Dis. 2022 Dec;22(12):1694&#x2013;1702. doi: 10.1016/S1473-3099(22)00449-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00449-2</ArticleId><ArticleId IdType="pmc">PMC9411260</ArticleId><ArticleId IdType="pubmed">36030795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantele A., L&#xe4;&#xe4;veri T., Kareinen L., Pakkanen S.H., Blomgren K., Mero S., et al. SARS-CoV-2 infections among healthcare workers at Helsinki University Hospital, Finland, spring 2020: serosurvey, symptoms and risk factors. Trav Med Infect Dis. 2021;39 doi: 10.1016/j.tmaid.2020.101949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101949</ArticleId><ArticleId IdType="pmc">PMC7833655</ArticleId><ArticleId IdType="pubmed">33321195</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Pan Z., Yue S., Yu F., Zhang J., Yang Y., et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal Transduct Targeted Ther. 2020;5:180. doi: 10.1038/s41392-020-00301-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00301-9</ArticleId><ArticleId IdType="pmc">PMC7464057</ArticleId><ArticleId IdType="pubmed">32879307</ArticleId></ArticleIdList></Reference><Reference><Citation>Sipil&#xe4; P.N., Heikkil&#xe4; N., Lindbohm J.V., Hakulinen C., Vahtera J., Elovainio M., et al. Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort. Lancet Infect Dis. 2021 Nov;21(11):1557&#x2013;1567. doi: 10.1016/S1473-3099(21)00144-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00144-4</ArticleId><ArticleId IdType="pmc">PMC8592915</ArticleId><ArticleId IdType="pubmed">34166620</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnish institute for health and welfare: Genomic surveillance of SARS-CoV-2. available at: https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-updates/coronavirus-variants/genomic-surveillance-of-sars-cov-2.</Citation></Reference><Reference><Citation>Antonelli M., Pujol J.C., Spector T.D., Ourselin S., Steves C.J. Risk of long COVID associated with Delta versus Omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>